| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Medicine [A. Y. C. C.] and Radiation Oncology [P. C. K.], University of Rochester School of Medicine and Dentistry, Rochester, New York 14642
Radiation sensitivity of human hypernephroma tumor cells, ACHN, was evaluated in the presence or absence of various recombinant interferons (IFNs):
D (rHuIFN-
D), ßser (rHuIFN-ßser), and
(rHuIFN-
). Exponentially growing monolayers of ACHN cells were incubated with IFNs (103 units/ml) for 2, 6, and 24 h prior to irradiation. The effects of IFNs on the growth inhibition, radiation cell survival, and cell cycle redistribution were determined from growth curves, colony-forming efficiency, and flow cytometric analysis. rHuIFN-
D and rHuIFN-ßser were associated with a modest inhibition in cell growth and the growth delay was reversible upon the removal of IFNs. However, rHuIFN-
exhibited the greatest inhibitory effect on both cell growth delay and rate. IFN and radiation have an additive effect on cell growth inhibition. Although IFN treatments alone (01000 IU/ml) did not have a significant effect on cell survival, radiation killing was increased by IFN pretreatment. The enhancing factor measured at a survival level of 0.1 for rHuIFN-
D, rHuIFN-ßser, and rHuIFN-
was 1.21, 1.28, and 1.44, respectively. In addition, this potentiation effect was dependent on the dose of radiation and exposure time to IFN with the maximal effect observed after 24 h of treatment with IFN at 12 Gy. When the distributions of G1, S, and G2-M cells were measured 24 and 48 h after combined IFN and radiation treatment, there was a significant increase in the accumulation of cells at the G2-M phase of the cell cycle compared to either IFN or radiation treatment alone. We conclude that IFNs and radiation have an additional inhibitory effect on ACHN cell growth, that IFN can potentiate radiation cytotoxicity, and that this phenomenon is associated with an increased blockage at G2-M phase of the cell cycle.
1 Supported by National Cancer Institute Grants CA-11051, CA-11198, and CA-28329.
2 To whom requests for reprints should be addressed, at St. Mary's Hospital, 89 Genesee St. Rochester, New York 14611.
Received 5/15/86. Revised 1/27/87. Revised 5/11/87. Accepted 5/14/87.
This article has been cited by other articles:
![]() |
L. Lasagni, M. Francalanci, F. Annunziato, E. Lazzeri, S. Giannini, L. Cosmi, C. Sagrinati, B. Mazzinghi, C. Orlando, E. Maggi, et al. An Alternatively Spliced Variant of CXCR3 Mediates the Inhibition of Endothelial Cell Growth Induced by IP-10, Mig, and I-TAC, and Acts as Functional Receptor for Platelet Factor 4 J. Exp. Med., June 2, 2003; 197(11): 1537 - 1549. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Malone, P. M. Schiltz, S. K. Nayak, M. W. Shea, and R. O. Dillman Combination Interferon-{{alpha}}2a and 13-cis-Retinoic Acid Enhances Radiosensitization of Human Malignant Glioma Cells in Vitro Clin. Cancer Res., February 1, 1999; 5(2): 417 - 423. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |